Christian Hartinger

List of Publications by Citations

243 papers	15,106 citations	68 h-index	117 g-index
265 ext. papers	16,245 ext. citations	5.6 avg, IF	6.66 L-index

#	Paper	IF	Citations
243	Bioorganometallic chemistry--from teaching paradigms to medicinal applications. *Chemical Society Reviews*, **2009**, 38, 391-401	58.5	840
242	From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). *Journal of Inorganic Biochemistry*, **2006**, 100, 891-904	4.2	806
241	Antitumour metal compounds: more than theme and variations. *Dalton Transactions*, **2008**, 183-94	4.3	702
240	KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. *Chemistry and Biodiversity*, **2008**, 5, 2140-55	2.5	624
239	Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. *Chemical Reviews*, **2006**, 106, 2224-48	68.1	528
238	Challenges and Opportunities in the Development of Organometallic Anticancer Drugs. *Organometallics*, **2012**, 31, 5677-5685	3.8	454
237	Anticancer activity of metal complexes: involvement of redox processes. *Antioxidants and Redox Signaling*, **2011**, 15, 1085-127	8.4	352
236	The development of RAPTA compounds for the treatment of tumors. *Coordination Chemistry Reviews*, **2016**, 306, 86-114	23.2	320
235	Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development. *Chemical Society Reviews*, **2018**, 47, 909-928	58.5	245
234	Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. *Journal of Medicinal Chemistry*, **2008**, 51, 6773-81	8.3	243
233	Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. *Journal of Inorganic Biochemistry*, **2008**, 102, 564-75	4.2	226
232	The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. *Journal of Biological Inorganic Chemistry*, **2008**, 13, 1149-55	3.7	210
231	Opening the lid on piano-stool complexes: An account of ruthenium(II) arene complexes with medicinal applications. *Journal of Organometallic Chemistry*, **2014**, 751, 251-260	2.3	206
230	Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. *Anti-Cancer Drugs*, **2009**, 20, 97-103	2.4	193
229	Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity. *Journal of Medicinal Chemistry*, **2007**, 50, 2185-93	8.3	191
228	Resistance against novel anticancer metal compounds: differences and similarities. *Drug Resistance Updates*, **2008**, 11, 1-16	23.2	183
227	Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. *Dalton Transactions*, **2006**, 1796-802	4.3	174

226	Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. *Journal of Analytical Atomic Spectrometry*, **2004**, 19, 46	3.7	174
225	Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium-Arene Compounds. *Organometallics*, **2008**, 27, 2405-2407	3.8	171
224	Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. *Journal of Medicinal Chemistry*, **2009**, 52, 916-25	8.3	156
223	A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core. *Chemistry - A European Journal*, **2011**, 17, 3562-6	4.8	149
222	Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. *Journal of Medicinal Chemistry*, **2005**, 48, 2831-7	8.3	145
221	Carbohydrate-metal complexes and their potential as anticancer agents. *Current Medicinal Chemistry*, **2008**, 15, 2574-91	4.3	137
220	Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder. *Chemical Communications*, **2012**, 48, 4839-41	5.8	125
219	Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin. *Electrophoresis*, **2004**, 25, 1988-95	3.6	120
218	Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands. *Journal of Medicinal Chemistry*, **2012**, 55, 10512-22	8.3	119
217	Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. *Dalton Transactions*, **2007**, 5065-72	4.3	119
216	Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. *Chemical Communications*, **2013**, 49, 3348-50	5.8	116
215	Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. *Chemical Society Reviews*, **2013**, 42, 6186-99	58.5	115
214	Development of anticancer agents: wizardry with osmium. *Drug Discovery Today*, **2014**, 19, 1640-8	8.8	113
213	Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action. *Chemical Science*, **2015**, 6, 2449-2456	9.4	105
212	Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies. *Journal of Biological Inorganic Chemistry*, **2013**, 18, 9-17	3.7	104
211	Platinum nanoparticles and their cellular uptake and DNA platination at non-cytotoxic concentrations. *Archives of Toxicology*, **2011**, 85, 799-812	5.8	104
210	Impact of the Halogen Substitution Pattern on the Biological Activity of Organoruthenium 8-Hydroxyquinoline Anticancer Agents. *Organometallics*, **2015**, 34, 5658-5668	3.8	102
209	Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro. *Chemistry - A European Journal*, **2009**, 15, 12283-91	4.8	102

208	Physicochemical Studies and Anticancer Potency of Ruthenium Ep-Cymene Complexes Containing Antibacterial Quinolones. *Organometallics*, **2011**, 30, 2506-2512	3.8	101
207	In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands. *Chemistry - A European Journal*, **2008**, 14, 9046-57	4.8	100
206	Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?. *Inorganic Chemistry*, **2010**, 49, 7953-63	5.1	98
205	Novel metal(II) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents. *Chemical Science*, **2013**, 4, 1837	9.4	95
204	Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds. *Journal of Inorganic Biochemistry*, **2008**, 102, 1066-76	4.2	95
203	Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)]. *Journal of Inorganic Biochemistry*, **2008**, 102, 1743-8	4.2	95
202	Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. *Journal of Inorganic Biochemistry*, **2011**, 105, 46-51	4.2	94
201	Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins. *Electrophoresis*, **2006**, 27, 1128-35	3.6	94
200	Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins. *Journal of Analytical Atomic Spectrometry*, **2005**, 20, 856	3.7	92
199	Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on the in Vitro Antitumor Activity of Polynuclear Organometallic Compounds. *Organometallics*, **2009**, 28, 6260-6265	3.8	90
198	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. *Journal of Analytical Atomic Spectrometry*, **2009**, 24, 51-61	3.7	88
197	Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach. *Inorganic Chemistry*, **2008**, 47, 17-9	5.1	87
196	CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. *Journal of Inorganic Biochemistry*, **2008**, 102, 1060-5	4.2	87
195	Anticancer metallodrugs: where is the next cisplatin?. *Future Medicinal Chemistry*, **2018**, 10, 615-617	4.1	85
194	Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules. *Chemical Communications*, **2012**, 48, 1475-7	5.8	82
193	Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma. *Electrophoresis*, **2008**, 29, 2224-32	3.6	82
192	Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences. *Dalton Transactions*, **2010**, 39, 7345-52	4.3	81
191	Mass spectrometric analysis of ubiquitinEplatinum interactions of leading anticancer drugs: MALDI versus ESI. *Journal of Analytical Atomic Spectrometry*, **2007**, 22, 960-967	3.7	81

190	Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis. *Analytical Biochemistry*, **2005**, 341, 326-33	3.1	80
189	From Pyrone to Thiopyrone Ligands Rendering Maltol-Derived Ruthenium(II) Arene Complexes That Are Anticancer Active in Vitro. *Organometallics*, **2009**, 28, 4249-4251	3.8	78
188	Pyrone derivatives and metals: From natural products to metal-based drugs. *Journal of Organometallic Chemistry*, **2011**, 696, 999-1010	2.3	77
187	Polynuclear ruthenium, osmium and gold complexes. The quest for innovative anticancer chemotherapeutics. *Current Topics in Medicinal Chemistry*, **2011**, 11, 2688-702	3	76
186	Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry. *Journal of Biological Inorganic Chemistry*, **2010**, 15, 677-88	3.7	75
185	DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media. *Biochemical Pharmacology*, **2009**, 77, 364-74	6	74
184	A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins. *Journal of Inorganic Biochemistry*, **2004**, 98, 1135-42	4.2	74
183	Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta. *Organometallics*, **2009**, 28, 1165-1172	3.8	73
182	Suzuki Coupling Reactions in Ether-Functionalized Ionic Liquids: The Importance of Weakly Interacting Cations. *Organometallics*, **2008**, 27, 3971-3977	3.8	73
181	Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action. *Journal of Inorganic Biochemistry*, **2016**, 160, 250-5	4.2	72
180	Anticancer Ruthenium(II)-p-cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives. *Organometallics*, **2014**, 33, 5546-5553	3.8	72
179	An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. *Angewandte Chemie - International Edition*, **2017**, 56, 8267-8271	16.4	71
178	3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands. *Dalton Transactions*, **2013**, 42, 6193-202	4.3	71
177	Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method. *Journal of Separation Science*, **2005**, 28, 121-7	3.4	70
176	Synthesis, cytotoxicity, and COMPARE analysis of ferrocene and [3]ferrocenophane tetrasubstituted olefin derivatives against human cancer cells. *ChemMedChem*, **2010**, 5, 2039-50	3.7	68
175	Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: synthesis, solution speciation and bioactivity. *Journal of Inorganic Biochemistry*, **2014**, 134, 57-65	4.2	64
174	Protein ruthenation and DNA alkylation: chlorambucil-functionalized RAPTA complexes and their anticancer activity. *Dalton Transactions*, **2015**, 44, 3614-23	4.3	63
173	From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands. *Journal of Inorganic Biochemistry*, **2011**, 105, 224-31	4.2	63

172	LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma. *Metallomics*, **2011**, 3, 1049-55	4.5	58
171	Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety. *Journal of Organometallic Chemistry*, **2009**, 694, 922-929	2.3	58
170	CE in anticancer metallodrug research--an update. *Electrophoresis*, **2007**, 28, 3436-46	3.6	58
169	Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity. *Journal of Inorganic Biochemistry*, **2008**, 102, 2136-41	4.2	57
168	Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends. *Analytical and Bioanalytical Chemistry*, **2013**, 405, 1791-808	4.4	55
167	Organometallic Antitumour Agents with Alternative Modes of Action. *Topics in Organometallic Chemistry*, **2010**, 57-80	0.6	55
166	High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides. *Inorganic Chemistry*, **2008**, 47, 10626-33	5.1	55
165	Nitrile-functionalized pyrrolidinium ionic liquids as solvents for cross-coupling reactions involving in situ generated nanoparticle catalyst reservoirs. *Physical Chemistry Chemical Physics*, **2010**, 12, 1834-41	3.6	54
164	Capillary electrophoresis in anti-cancer metallodrug research: advances and future challenges. *Electrophoresis*, **2003**, 24, 2023-37	3.6	54
163	Synthesis and Biological Evaluation of the Thionated Antibacterial Agent Nalidixic Acid and Its Organoruthenium(II) Complex. *Organometallics*, **2012**, 31, 5867-5874	3.8	53
162	Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. *Metallomics*, **2014**, 6, 1616-25	4.5	52
161	Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guanosine 5′-monophosphate O6-N7 chelation. *ChemBioChem*, **2004**, 5, 1543-9	3.8	50
160	Half-sandwich ruthenium(II) biotin conjugates as biological vectors to cancer cells. *Chemistry - A European Journal*, **2015**, 21, 5110-7	4.8	49
159	Biomolecule binding vs. anticancer activity: reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins. *Journal of Inorganic Biochemistry*, **2012**, 108, 91-5	4.2	49
158	Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. *Journal of Biological Inorganic Chemistry*, **2012**, 17, 465-74	3.7	49
157	Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate. *Chemistry - A European Journal*, **2013**, 19, 9297-307	4.8	48
156	Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands. *Molecular Pharmacology*, **2007**, 71, 357-65	4.3	48
155	A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?. *ChemMedChem*, **2007**, 2, 505-14	3.7	47

154	A Reduced-Symmetry Heterobimetallic [PdPtL] Cage: Assembly, Guest Binding, and Stimulus-Induced Switching. *Angewandte Chemie - International Edition*, **2020**, 59, 11101-11107	16.4	46
153	Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds. *Inorganic Chemistry*, **2012**, 51, 3633-9	5.1	46
152	Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE. *Electrophoresis*, **2007**, 28, 2235-40	3.6	45
151	Modifying the structure of dinuclear ruthenium complexes with antitumor activity. *Applied Organometallic Chemistry*, **2008**, 22, 326-332	3.1	45
150	Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato-2N,O)platinum(II) a representative of novel pH sensitive anticancer platinum complexes. *Inorganica Chimica Acta*, **2004**, 357, 3237-3244	2.7	45
149	The first example of MEEKC-ICP-MS coupling and its application for the analysis of anticancer platinum complexes. *Electrophoresis*, **2010**, 31, 1144-50	3.6	44
148	Metallodrug research and analysis using capillary electrophoresis. *TrAC - Trends in Analytical Chemistry*, **2006**, 25, 868-875	14.6	44
147	Comparative solution equilibrium studies of anticancer gallium(III) complexes of 8-hydroxyquinoline and hydroxy(thio)pyrone ligands. *Journal of Inorganic Biochemistry*, **2012**, 117, 189-97	4.2	43
146	{(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo. *Journal of Medicinal Chemistry*, **2010**, 53, 7356-64	8.3	43
145	The serum protein binding of pharmacologically active gallium(III) compounds assessed by hyphenated CE-MS techniques. *Electrophoresis*, **2009**, 30, 2720-7	3.6	43
144	Metabolization of [Ru(eta(6)-C (6)H (5)CF (3))(pta)Cl (2)]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand. *Journal of Biological Inorganic Chemistry*, **2010**, 15, 919-27	3.7	43
143	Anticancer activity of methyl-substituted oxaliplatin analogs. *Molecular Pharmacology*, **2012**, 81, 719-28	4.3	39
142	Ruthenium and Other Non-Platinum Anticancer Compounds **2011**, 151-174		39
141	Fragmentation methods on the balance: unambiguous top-down mass spectrometric characterization of oxaliplatin-ubiquitin binding sites. *Analytical and Bioanalytical Chemistry*, **2012**, 402, 2655-62	4.4	38
140	Towards targeting anticancer drugs: ruthenium(ii)-arene complexes with biologically active naphthoquinone-derived ligand systems. *Dalton Transactions*, **2016**, 45, 13091-103	4.3	38
139	From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived N-Heterocyclic-Carbene Complexes as Anticancer Agents. *Inorganic Chemistry*, **2018**, 57, 14427-14434	5.1	38
138	Tumor-inhibiting platinum(II) complexes with aminoalcohol ligands: comparison of the mode of action by capillary electrophoresis and electrospray ionization-mass spectrometry. *Electrophoresis*, **2003**, 24, 2038-44	3.6	36
137	Metal complexes of benzimidazole derived sulfonamide: Synthesis, molecular structures and antimicrobial activity. *Inorganica Chimica Acta*, **2016**, 443, 179-185	2.7	33

136	Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication. *Chemistry and Biodiversity*, **2008**, 5, 1609-14	2.5	32
135	Chemical imaging and assessment of cadmium distribution in the human body. *Metallomics*, **2019**, 11, 2010-2019	4.5	32
134	The metalation of hen egg white lysozyme impacts protein stability as shown by ion mobility mass spectrometry, differential scanning calorimetry, and X-ray crystallography. *Chemical Communications*, **2017**, 53, 4246-4249	5.8	31
133	Anticancer activity of Ru- and Os(arene) compounds of a maleimide-functionalized bioactive pyridinecarbothioamide ligand. *Journal of Inorganic Biochemistry*, **2016**, 165, 100-107	4.2	31
132	A new target for gold(I) compounds: glutathione-S-transferase inhibition by auranofin. *Journal of Inorganic Biochemistry*, **2013**, 119, 38-42	4.2	31
131	Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis. *Journal of Chromatography A*, **2007**, 1155, 218-21	4.5	31
130	(Pyridin-2-yl)-NHC Organoruthenium Complexes: Antiproliferative Properties and Reactivity toward Biomolecules. *Organometallics*, **2018**, 37, 1575-1584	3.8	30
129	Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol Ruthenium(II)(η6-Arene) Complexes. *Australian Journal of Chemistry*, **2010**, 63, 1521	1.2	30
128	New Insights into the Chemistry of the Antineoplastic Lanthanum Complex Tris(1,10-phenanthroline)tris(thiocyanato-κN)lanthanum(III) (KP772) and Its Interaction with Biomolecules. *European Journal of Inorganic Chemistry*, **2009**, 2009, 4282-4287	2.3	30
127	Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os. *Chemistry - A European Journal*, **2017**, 23, 4893-4902	4.8	29
126	Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development. *Chemistry - A European Journal*, **2013**, 19, 4308-18	4.8	29
125	Potent Inhibition of Thioredoxin Reductase by the Rh Derivatives of Anticancer M(arene/Cp*)(NHC)Cl Complexes. *Inorganic Chemistry*, **2020**, 59, 3281-3289	5.1	28
124	Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. *Inorganic Chemistry*, **2018**, 57, 2851-2864	5.1	28
123	Making organoruthenium complexes of 8-hydroxyquinolines more hydrophilic: impact of a novel l-phenylalanine-derived arene ligand on the biological activity. *Dalton Transactions*, **2018**, 47, 2192-2201	4.3	28
122	Novel glucose-ferrocenyl derivatives: synthesis and properties. *New Journal of Chemistry*, **2002**, 26, 671-673	3.3	28
121	Anticancer organorhodium and -iridium complexes with low toxicity in vivo but high potency in vitro: DNA damage, reactive oxygen species formation, and haemolytic activity. *Chemical Communications*, **2019**, 55, 12016-12019	5.8	27
120	Organoruthenium and Osmium Anticancer Complexes Bearing a Maleimide Functional Group: Reactivity to Cysteine, Stability, and Cytotoxicity. *ChemPlusChem*, **2015**, 80, 231-236	2.8	27
119	Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein-Ru(carbene) adduct. *Chemical Communications*, **2018**, 54, 6120-6123	5.8	26

118	Extravasation of Pt-based chemotherapeutics - bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS). *Metallomics*, **2015**, 7, 508-15	4.5	25
117	DNA interactions of pH-sensitive, antitumor bis(aminoalcohol)dichloroplatinum(II) complexes. *Biochemistry*, **2006**, 45, 14817-25	3.2	25
116	Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay. *Journal of Inorganic Biochemistry*, **2017**, 177, 322-327	4.2	24
115	Mannich products of kojic acid and N-heterocycles and their Ru(II)arene complexes: Synthesis, characterization and stability. *Journal of Organometallic Chemistry*, **2010**, 695, 875-881	2.3	24
114	Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro protein-binding studies by means of CZE-ICP-MS. *Electrophoresis*, **2009**, 30, 4075-82	3.6	23
113	Cationic Ru(-p-cymene) Complexes of 3-Hydroxy-4-pyr(id)ones Lipophilic Triphenylphosphine as Co-Ligand Is Key to Highly Stable and Cytotoxic Anticancer Agents. *European Journal of Inorganic Chemistry*, **2017**, 2017, 1721-1727	2.3	22
112	Phosphite-derivatized ruthenium-carbohydrate complexes in the catalytic hydration of nitriles. short communication. *Chemistry and Biodiversity*, **2008**, 5, 1640-4	2.5	22
111	Synthesis of ferrocenylglucose phosphonite and bisphosphinite: Pd(II) and Pt(II) complexes, Pd-catalyzed allylic alkylation. *Tetrahedron*, **2002**, 58, 8489-8492	2.4	22
110	Hydroxyquinoline-derived anticancer organometallics: Introduction of amphiphilic PTA as an ancillary ligand increases their aqueous solubility. *Journal of Inorganic Biochemistry*, **2019**, 199, 110768	4.2	21
109	RutheniumII(-arene) complexes of thiourea derivatives: synthesis, characterization and urease inhibition. *Molecules*, **2014**, 19, 8080-92	4.8	21
108	DNA damaging properties of single walled carbon nanotubes in human colon carcinoma cells. *Nanotoxicology*, **2013**, 7, 2-20	5.3	21
107	Anticancer Ru(-p-cymene) complexes of 2-pyridinecarbothioamides: A structure-activity relationship study. *Journal of Inorganic Biochemistry*, **2017**, 177, 395-401	4.2	21
106	DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metallodrug binding selectivity. *Chemical Communications*, **2017**, 53, 8002-8005	5.8	21
105	Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications. *Electrophoresis*, **2012**, 33, 622-34	3.6	21
104	The hydration of chloroacetonitriles catalyzed by mono- and dinuclear Ru(II)- and Os(II)-arene complexes. *Chemistry and Biodiversity*, **2008**, 5, 2060-6	2.5	21
103	Tumour-inhibiting platinum(II) complexes with aminoalcohol ligands: biologically important transformations studied by micellar electrokinetic chromatography, nuclear magnetic resonance spectroscopy and mass spectrometry. *Analyst, The*, **2005**, 130, 1383-9	5	21
102	Structural Modifications of the Antiinflammatory Oxicam Scaffold and Preparation of Anticancer Organometallic Compounds. *Organometallics*, **2019**, 38, 361-374	3.8	21
101	Interactions of the carrier ligands of antidiabetic metal complexes with human serum albumin: a combined spectroscopic and separation approach with molecular modeling studies. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 4202-10	3.4	20

100	Flavonoid-Based Organometallics with Different Metal Centers Investigations of the Effects on Reactivity and Cytotoxicity. *European Journal of Inorganic Chemistry*, **2016**, 2016, 240-246	2.3	19
99	Solution equilibria of anticancer ruthenium(II)-(6)-p-cymene)-hydroxy(thio)pyr(id)one complexes: impact of sulfur vs. oxygen donor systems on the speciation and bioactivity. *Journal of Inorganic Biochemistry*, **2013**, 127, 161-8	4.2	19
98	Solution equilibrium studies on anticancer ruthenium(II)-p-cymene complexes of 3-hydroxy-2(1H)-pyridones. *Journal of Organometallic Chemistry*, **2013**, 734, 38-44	2.3	19
97	Electrophoretic separation techniques and their hyphenation to mass spectrometry in biological inorganic chemistry. *Electrophoresis*, **2016**, 37, 959-72	3.6	19
96	A Bioactive l-Phenylalanine-Derived Arene in Multitargeted Organoruthenium Compounds: Impact on the Antiproliferative Activity and Mode of Action. *Inorganic Chemistry*, **2018**, 57, 8521-8529	5.1	18
95	An internal fluorescent probe based on anthracene to evaluate cation-anion interactions in imidazolium salts. *Chemistry - A European Journal*, **2010**, 16, 6473-81	4.8	18
94	Ferrocenyl Paclitaxel and Docetaxel Derivatives: Impact of an Organometallic Moiety on the Mode of Action of Taxanes. *Chemistry - A European Journal*, **2016**, 22, 11413-21	4.8	18
93	Aspirin-inspired organometallic compounds: Structural characterization and cytotoxicity. *Journal of Organometallic Chemistry*, **2017**, 839, 31-37	2.3	17
92	A Reduced-Symmetry Heterobimetallic [PdPtL4]4+ Cage: Assembly, Guest Binding, and Stimulus-Induced Switching. *Angewandte Chemie*, **2020**, 132, 11194-11200	3.6	17
91	Advanced metallomics methods in anticancer metallodrug mode of action studies. *TrAC - Trends in Analytical Chemistry*, **2018**, 104, 110-117	14.6	17
90	Monodentately-coordinated bioactive moieties in multimodal half-sandwich organoruthenium anticancer agents. *Coordination Chemistry Reviews*, **2021**, 439, 213890	23.2	17
89	RuII(-p-cymene) Complexes of Bioactive 1,2-Benzothiazines: Protein Binding vs. Antitumor Activity. *European Journal of Inorganic Chemistry*, **2016**, 2016, 1376-1382	2.3	17
88	Organometallic ruthenium and osmium compounds of pyridin-2- and -4-ones as potential anticancer agents. *Chemistry and Biodiversity*, **2012**, 9, 1718-27	2.5	16
87	Influence of the coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes. *Frontiers in Chemistry*, **2013**, 1, 27	5	16
86	Rhodium(Cp*) Compounds with Flavone-derived Ligand Systems: Synthesis and Characterization. *Zeitschrift Fur Anorganische Und Allgemeine Chemie*, **2013**, 639, 1648-1654	1.3	15
85	Capillary zone electrophoresis and capillary zone electrophoresis-electrospray ionization mass spectrometry studies on the behavior of anticancer cis- and trans-[dihalidobis(2-propanone oxime)platinum(II)] complexes in aqueous solutions. *Journal of Chromatography A*, **2012**, 1267, 156-61	4.5	15
84	Trapping unstable benzoquinone analogues by coordination to a [(5)-C(5)Me(5))Ir] fragment and the anticancer activity of the resulting complexes. *Angewandte Chemie - International Edition*, **2010**, 49, 8304-5	16.4	15
83	Glucose ferrocenyl-oxazolines: Coordination behavior toward [Pd(-allyl)Cl]2 studied by ESI-MS. *Journal of Organometallic Chemistry*, **2005**, 690, 3301-3308	2.3	15

82	Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC-ICP-MS. *Monatshefte F□ Chemie*, **2018**, 149, 1719-1726	1.4	15
81	Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes. *Journal of Biological Inorganic Chemistry*, **2013**, 18, 249-60	3.7	14
80	Analysis of ruthenium anticancer agents by MEEKC-UV and MEEKC-ICP-MS: Impact of structural motifs on lipophilicity and biological activity. *Electrophoresis*, **2018**, 39, 1201-1207	3.6	13
79	A systematic capillary electrophoresis study on the effect of the buffer composition on the reactivity of the anticancer drug cisplatin to the DNA model 2N-deoxyguanosine 5N-monophosphate (dGMP). *Analytical and Bioanalytical Chemistry*, **2013**, 405, 6417-24	4.4	13
78	1,1N-Bis(oxazolin-2-yl)ferrocenes: An Investigation of Their Complexation Behavior toward [Pd(□3-allyl)Cl]2. *European Journal of Inorganic Chemistry*, **2005**, 2005, 1589-1600	2.3	13
77	Functionalization of Ruthenium(II)(□6-p-cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies. *ChemPlusChem*, **2017**, 82, 841-847	2.8	12
76	Coordination Chemistry of Organoruthenium Compounds with Benzoylthiourea Ligands and their Biological Properties. *Chemistry - an Asian Journal*, **2019**, 14, 1262-1270	4.5	12
75	A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. *Angewandte Chemie - International Edition*, **2020**, 59, 14609-14614	16.4	12
74	Expanding on the Structural Diversity of Flavone- Derived RutheniumII(□6-arene) Anticancer Agents **2015**, 1,		12
73	Solution equilibrium studies of anticancer ruthenium(II)-□6-p-cymene complexes of pyridinecarboxylic acids. *Polyhedron*, **2014**, 67, 51-58	2.7	12
72	Synthesis and characterisation of the water soluble bis-phosphine complex [Ru(□6-cymene)(PPh2(o-C6H4O)-□2-P,O)(pta)]+ and an investigation of its cytotoxic effects. *Comptes Rendus Chimie*, **2010**, 13, 1144-1150	2.7	12
71	A Combined Spectroscopic and Protein Crystallography Study Reveals Protein Interactions of Rh(NHC) Complexes at the Molecular Level. *Inorganic Chemistry*, **2020**, 59, 17191-17199	5.1	12
70	Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies. *Inorganica Chimica Acta*, **2016**, 450, 124-130	2.7	12
69	Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands. *Coordination Chemistry Reviews*, **2021**, 445, 213950	23.2	12
68	Metallomic study on the metabolism of RAPTA-C and cisplatin in cell culture medium and its impact on cell accumulation. *Metallomics*, **2018**, 10, 455-462	4.5	11
67	Quinoline-para-quinones and metals: coordination-assisted formation of quinoline-ortho-quinones. *Chemical Communications*, **2018**, 54, 992-995	5.8	11
66	Efficiently detecting metallodrug-protein adducts: ion trap versus time-of-flight mass analyzers. *ChemMedChem*, **2014**, 9, 1351-5	3.7	11
65	Synthesis and in vitro Biological Evaluation of Ferrocenyl Side-Chain-Functionalized Paclitaxel Derivatives. *ChemMedChem*, **2017**, 12, 1882-1892	3.7	11

64	Ein Organoruthenium-Tumortherapeutikum mit unerwartet hoher Selektivität für Plectin. *Angewandte Chemie*, **2017**, 129, 8379-8383	3.6	11
63	Physicochemical studies on the copper(II) binding by glycated collagen telopeptides. *Organic and Biomolecular Chemistry*, **2015**, 13, 3058-63	3.9	10
62	Synthesis of [RuII(η6-p-cymene)(PPh3)(L)Cl]PF6 complexes with carbohydrate-derived phosphites, imidazole or indazole co-ligands. *Inorganica Chimica Acta*, **2012**, 380, 211-215	2.7	10
61	A one step/one pot synthesis of N,N-bis(phosphonomethyl)amino acids and their effects on adipogenic and osteogenic differentiation of human mesenchymal stem cells. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 3388-93	3.4	10
60	Biological properties of ruthenium(II)/(III) complexes with flavonoids as ligands. *Coordination Chemistry Reviews*, **2021**, 436, 213849	23.2	10
59	Probing the Paradigm of Promiscuity for N-Heterocyclic Carbene Complexes and their Protein Adduct Formation. *Angewandte Chemie - International Edition*, **2021**, 60, 19928-19932	16.4	10
58	Organoruthenium and Organoosmium Complexes of 2-Pyridinecarbothioamides Functionalized with a Sulfonamide Motif: Synthesis, Cytotoxicity and Biomolecule Interactions. *ChemPlusChem*, **2018**, 83, 612-619	2.8	9
57	Capillary electrophoresis in metallodrug development. *Drug Discovery Today: Technologies*, **2015**, 16, 16-22	7.1	8
56	The rearrangement of tosylated flavones to 1?-(alkylamino)aurones with primary amines. *Tetrahedron*, **2015**, 71, 8953-8959	2.4	8
55	Medicinal Chemistry of Gold Anticancer Metallodrugs. *Metal Ions in Life Sciences*, **2018**, 18,	2.6	8
54	Metalloproteomics for molecular target identification of protein-binding anticancer metallodrugs. *Metallomics*, **2020**, 12, 1627-1636	4.5	8
53	Mustards-Derived Terpyridine-Platinum Complexes as Anticancer Agents: DNA Alkylation vs Coordination. *Inorganic Chemistry*, **2021**, 60, 2414-2424	5.1	8
52	Understanding the interactions of diruthenium anticancer agents with amino acids. *Journal of Biological Inorganic Chemistry*, **2018**, 23, 1159-1164	3.7	7
51	Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. *Dalton Transactions*, **2014**, 43, 9851-5	4.3	7
50	Methyl-substituted trans-1,2-cyclohexanediamines as new ligands for oxaliplatin-type complexes. *Tetrahedron*, **2008**, 64, 137-146	2.4	7
49	Synthesis, crystal structures, and electrospray ionisation mass spectrometry investigations of ether- and thioether-substituted ferrocenes. *Dalton Transactions*, **2003**, 3098	4.3	7
48	Hybrid compounds from chalcone and 1,2-benzothiazine pharmacophores as selective inhibitors of alkaline phosphatase isozymes. *European Journal of Medicinal Chemistry*, **2018**, 159, 282-291	6.8	7
47	Anthracenyl Functionalization of Half-Sandwich Carbene Complexes: Anticancer Activity and Reactions with Biomolecules. *Inorganic Chemistry*, **2021**, 60, 14636-14644	5.1	7

46	Bis- and tris-bicyclophosphites of d-glucofuranoside. Unexpected catalysis of P(III/V)-oxidation by triethylamine. *Tetrahedron*, **2005**, 61, 10943-10950	2.4	6
45	Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands. *Inorganic Chemistry*, **2020**, 59, 14879-14890	5.1	6
44	Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells. *Pharmaceuticals*, **2021**, 14,	5.2	6
43	Linked Metal-cluster Systems: Isolation and Characterisation of {anti-[(p-cymene)RuCl]-[□2-P,P?;□ 1-P??-(PPh2CH2)3CMe]-[AuPt3(CO)3(PCy3)3]}(PF6)2. *Journal of Cluster Science*, **2008**, 19, 295-309	3	5
42	Electrospray ionization mass spectrometric study on the coordination behavior of dacarbazine towards transition metal ions. *Polyhedron*, **2006**, 25, 1971-1978	2.7	5
41	1,1,3,3-Tetramethyl-1,3-disila-2-oxa[3]ferrocenophane: improved synthesis and new crystal structure. *Inorganica Chimica Acta*, **2002**, 328, 237-240	2.7	5
40	Thiourea-Derived Chelating Ligands and Their Organometallic Compounds: Investigations into Their Anticancer Activity. *Molecules*, **2020**, 25,	4.8	5
39	Hyphenation of capillary electrophoresis to inductively coupled plasma mass spectrometry with a modified coaxial sheath-flow interface. *Journal of Chromatography A*, **2018**, 1561, 76-82	4.5	5
38	AAS, XRF, and MS Methods in Chemical Biology of Metal Complexes63-97		5
37	Heterotrimetallic Double Cavity Cages: Syntheses and Selective Guest Binding.. *Angewandte Chemie - International Edition*, **2022**, e202201700	16.4	5
36	Cobalt complexes as internal standards for capillary zone electrophoresis-mass spectrometry studies in biological inorganic chemistry. *Journal of Biological Inorganic Chemistry*, **2017**, 22, 789-798	3.7	4
35	Gel electrophoresis in combination with laser ablation-inductively coupled plasma mass spectrometry to quantify the interaction of cisplatin with human serum albumin. *Electrophoresis*, **2019**, 40, 2329-2335	3.6	4
34	Antitumor Metallodrugs that Target Proteins. *Metal Ions in Life Sciences*, **2018**, 18,	2.6	4
33	Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. *Pharmaceuticals*, **2021**, 14,	5.2	4
32	Heptadentate, Octadentate, Or Even Nonadentate? Denticity in the Unexpected Formation of an All-Carbon Donor-Atom Ligand in Rh(Cp*)(Anthracenyl-NHC) Complexes. *Inorganic Chemistry*, **2021**, 60, 8734-8741	5.1	4
31	Medicinal Chemistry **2019**, 157-172		3
30	Triazolyl-Functionalized N-Heterocyclic Carbene Half-Sandwich Compounds: Coordination Mode, Reactivity and in vitro Anticancer Activity. *ChemMedChem*, **2021**, 16, 3017-3026	3.7	3
29	Ruthenium Anticancer Agents□rom Cisplatin Analogues to Rational Drug Design **2017**, 1-21		2

28	Comparative solution studies and cytotoxicity of gallium(III) and iron(III) complexes of 3-hydroxy-2(1H)-pyridinones. *Polyhedron*, **2019**, 172, 141-147	2.7	2
27	Reprint of: Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies. *Inorganica Chimica Acta*, **2017**, 454, 247-253	2.7	2
26	Isolierung instabiler Benzochinonanaloga durch Koordination an ein [(η5-C5Me5)Ir]-Fragment und tumorhemmende Aktivität der resultierenden Komplexe. *Angewandte Chemie*, **2010**, 122, 8482-8483	3.6	2
25	On the Coordination Properties of New Bicyclophosphite-Carbohydrates. *Monatshefte Für Chemie*, **2005**, 136, 137-146	1.4	2
24	5-Hydr-oxy-2-methyl-4H-pyran-4-one. *Acta Crystallographica Section E: Structure Reports Online*, **2009**, 65, o437		2
23	From the hypothesis-driven development of organometallic anticancer drugs to new methods in mode of action studies. *Advances in Inorganic Chemistry*, **2020**, 75, 339-359	2.1	2
22	Homodinuclear organometallics of ditopic N,N-chelates: Synthesis, reactivity and in vitro anticancer activity. *Inorganica Chimica Acta*, **2021**, 518, 120220	2.7	2
21	Carbon Monoxide is an Inhibitor of HIF Prolyl Hydroxylase Domain 2. *ChemBioChem*, **2021**, 22, 2521-2525	3.8	2
20	Cavity-Containing [FeL] Helicates: An Examination of Host-Guest Chemistry and Cytotoxicity. *Frontiers in Chemistry*, **2021**, 9, 697684	5	2
19	Tracing the anticancer compound [Ru(η6-p-cymene)(8-oxyquinolinato)Cl] in a biological environment by mass spectrometric methods. *Analytical Methods*, **2021**, 13, 1463-1469	3.2	2
18	High Antiproliferative Activity of Hydroxythiopyridones over Hydroxypyridones and Their Organoruthenium Complexes. *Biomedicines*, **2021**, 9,	4.8	2
17	Impact of the Metal Center and Leaving Group on the Anticancer Activity of Organometallic Complexes of Pyridine-2-carbothioamide. *Molecules*, **2021**, 26,	4.8	2
16	A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. *Angewandte Chemie*, **2020**, 132, 14717-14722	3.6	2
15	Incorporation of βAlanine in Cu(II) ATCUN Peptide Complexes Increases ROS Levels, DNA Cleavage and Antiproliferative Activity*. *Chemistry - A European Journal*, **2021**, 27, 18093	4.8	1
14	Dinuclear orthometallated gold(I)-gold(III) anticancer complexes with potent in vivo activity through an ROS-dependent mechanism. *Metallomics*, **2021**, 13,	4.5	1
13	Synthetic Strategy Towards Heterodimetallic Half-Sandwich Complexes Based on a Symmetric Ditopic Ligand.. *Frontiers in Chemistry*, **2021**, 9, 786367	5	0
12	Probing the Paradigm of Promiscuity for N-Heterocyclic Carbene Complexes and their Protein Adduct Formation. *Angewandte Chemie*, **2021**, 133, 20081-20085	3.6	0
11	In-flow SAXS investigation of whey protein isolate hydrolyzed by bromelain. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, **2021**, 631, 127662	5.1	0

10	Substitution of the chlorido ligand for PPh3 in anticancer organoruthenium complexes of sulfonamide-functionalized pyridine-2-carbothioamides leads to high cytotoxic activity. *Inorganica Chimica Acta*, **2022**, 536, 120889	2.7	0
9	Design of organoruthenium complexes for nanoparticle functionalization. *Journal of Organometallic Chemistry*, **2019**, 891, 64-71	2.3	
8	Innenrücktitelbild: Ein Organoruthenium-Tumortherapeutikum mit unerwartet hoher Selektivität für Plectin (Angew. Chem. 28/2017). *Angewandte Chemie*, **2017**, 129, 8415-8415	3.6	
7	Ruthenium Anticancer Agents En Route to the Tumor **2017**, 161-180		
6	The Analysis of Therapeutic Metal Complexes and Their Biomolecular Interactions **2017**, 355-386		
5	Letters to a Young Chemist. Herausgegeben von Abhik Ghosh.. *Angewandte Chemie*, **2011**, 123, 12604-12605	3.6	
4	Crystallographic report: Crystal structure of 1-bromo-1?-[(2S)-N-(1-hydroxy-3-methylbutane-2-yl)]-ferroceneamide. *Applied Organometallic Chemistry*, **2003**, 17, 723-724	3.1	
3	Metal Compounds as Kinase and Phosphatase Inhibitors in Drug Development: The Role of the Metal and Ligands301-330		
2	Organometallics in Cancer Treatment: Non-conventional Structures and Modes of Action **2018**,		
1	Determination of Relative Stabilities of Metal-Peptide Bonds in the Gas Phase. *Chemistry - A European Journal*, **2021**, 27, 16401-16406	4.8	